Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Status:
Recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
SCR-ESCC-02 is a multicenter, phase I/II clinical study to investigate the safety and
efficacy of induction immunochemotherapy followed by concurrent chemoradiotherapy with
anti-PD-1 therapy in patients diagnosed with locally advanced, unresectable esophageal
cancer.